These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17066280

  • 21. Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding.
    Latif S, Fraga G, Gadzia J.
    J Drugs Dermatol; 2010 Mar; 9(3):268-70. PubMed ID: 20232590
    [Abstract] [Full Text] [Related]

  • 22. [A case of severe hand-foot syndrome caused by capecitabine].
    Shimomatsuya T, Mitsudou Y, Nakamura T, Yonezawa K, Shiraishi S, Fujino M, Maruhashi K.
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1139-41. PubMed ID: 17637558
    [Abstract] [Full Text] [Related]

  • 23. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I, Guzin G.
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [Abstract] [Full Text] [Related]

  • 24. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O, Saif MW.
    Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
    [Abstract] [Full Text] [Related]

  • 25. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
    Maino KL, Norwood C, Stashower ME.
    Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
    [Abstract] [Full Text] [Related]

  • 26. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
    Son HS, Lee WY, Lee WS, Yun SH, Chun HK.
    Yonsei Med J; 2009 Dec 31; 50(6):796-802. PubMed ID: 20046420
    [Abstract] [Full Text] [Related]

  • 27. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J, Tauchert F, Al-Batran SE, Schneeweiss A.
    J Clin Oncol; 2015 Aug 01; 33(22):2444-9. PubMed ID: 26124485
    [Abstract] [Full Text] [Related]

  • 28. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
    Narasimhan P, Narasimhan S, Hitti IF, Rachita M.
    Cutis; 2004 Feb 01; 73(2):101-6. PubMed ID: 15027515
    [Abstract] [Full Text] [Related]

  • 29. [Capecitabine-induced hyperpigmentation].
    Vázquez-Bayo C, Rodríguez-Bujaldón AL, Jiménez-Puya R, Galán-Gutiérrez M, Moreno-Giménez JC.
    Actas Dermosifiliogr; 2007 Sep 01; 98(7):491-3. PubMed ID: 17669305
    [Abstract] [Full Text] [Related]

  • 30. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
    Chan HY, Ng CM, Tiu SC, Chan AO, Shek CC.
    Hong Kong Med J; 2012 Dec 01; 18(6):526-9. PubMed ID: 23223655
    [Abstract] [Full Text] [Related]

  • 31. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y, Hoff P.
    Eur J Oncol Nurs; 2004 Dec 01; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [Abstract] [Full Text] [Related]

  • 32. Could the hand-foot syndrome after capecitabine treatment be associated with better outcome in metastatic breast cancer patients?
    Kurt M, Aksoy S, Guler N.
    Acta Oncol; 2006 Dec 01; 45(5):625-6. PubMed ID: 16864181
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
    Wang Y, Yang H, Wei JF, Meng L.
    Curr Med Res Opin; 2012 Dec 01; 28(12):1911-9. PubMed ID: 23145857
    [Abstract] [Full Text] [Related]

  • 34. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
    Mignogna MD, Fortuna G, Falleti J, Leuci S.
    Eur J Clin Pharmacol; 2009 Oct 01; 65(10):1057-9. PubMed ID: 19521695
    [No Abstract] [Full Text] [Related]

  • 35. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
    Vickers MM, Easaw JC.
    J Gastrointest Cancer; 2008 Oct 01; 39(1-4):141-3. PubMed ID: 19440857
    [Abstract] [Full Text] [Related]

  • 36. [A case of palmoplantar dysesthesia syndrome caused by capecitabine].
    Elmas ÖF, Metin MS, Kızılyel O, Aktaş A, Birdal C.
    Agri; 2016 Jan 01; 28(1):54-6. PubMed ID: 27225615
    [Abstract] [Full Text] [Related]

  • 37. Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
    Peramiquel L, Dalmau J, Puig L, Roé E, Fernández-Figueras MT, Alomar A.
    J Am Acad Dermatol; 2006 Nov 01; 55(5 Suppl):S119-20. PubMed ID: 17052530
    [No Abstract] [Full Text] [Related]

  • 38. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC, Chung HC.
    Asia Pac J Clin Oncol; 2010 Sep 01; 6(3):141-3. PubMed ID: 20887492
    [No Abstract] [Full Text] [Related]

  • 39. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T, Tantiphlachiva K, Suwanrusme H, Voravud N, Sriuranpong V.
    Asia Pac J Clin Oncol; 2010 Sep 01; 6(3):155-60. PubMed ID: 20887495
    [Abstract] [Full Text] [Related]

  • 40. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H, Jiang Z, Wang T, Zhang S, Bian L, Cao Y, Wu S, Song S.
    Anticancer Drugs; 2012 Aug 01; 23(7):718-23. PubMed ID: 22739713
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.